Is Credit Suisse Group AG (CS) a Buy, Sell, or Hold?
NYSE : CS
Credit Suisse Group AG — News
$0.8858 USD
$0.01 (0.99%)
- Volume
- 63.95M
- Average Volume
- 26.25M
- Market Capitalization
- $3.5B
- P/E Ratio
- -0.24
- Dividend Yield
- 16.97%
- Price Target
- $12.00
- Year High
- $6.08
- Year Low
- $0.82
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$0.04
- Current Ratio
- $3.54
| Source | Headline |
|---|---|
|
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase 2 BEACON) and has received FDA Breakthrough Therapy Designation for CS Global Phase 3 study (BEACON+) is underway, evaluating brepocitinib 45 mg once daily against placebo in 140 patients across approximately 70 sites globally; BEACON+ topline data expected in calendar year 2028 Brepocitinib's development program now includes four indications with ongoing or successfully completed registrational trials: dermatomyositis (DM), non-infectious uveitis (NIU), lichen planopilaris (LPP), and CS; potential NDA approval and product launch in DM expected by the end of September 2026 DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Priovant today announced that the first patients have been enrolled in the Phase 3 study evaluating brepocitinib in cutaneous sarcoidosis (CS). globenewswire.com - 2026-08-06 07:00:00 |
|
Alcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada
MONTRÉAL--(BUSINESS WIRE)--Alcon announces the launch and Canadian availability of UNITY® Cataract System (CS), Alcon's next-generation standalone cataract surgical platform. businesswire.com - 2026-06-15 09:43:00 |
